Compare NHI & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NHI | AMLX |
|---|---|---|
| Founded | 1991 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.8B |
| IPO Year | 1994 | 2021 |
| Metric | NHI | AMLX |
|---|---|---|
| Price | $70.32 | $31.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $87.00 | $21.56 |
| AVG Volume (30 Days) | 289.4K | ★ 3.2M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.81% | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ 1.97 | N/A |
| Revenue | $375,628,000.00 | ★ $380,786,000.00 |
| Revenue This Year | $15.44 | N/A |
| Revenue Next Year | $10.01 | N/A |
| P/E Ratio | $35.63 | ★ N/A |
| Revenue Growth | 12.07 | ★ 1612.94 |
| 52 Week Low | $67.94 | $10.83 |
| 52 Week High | $91.38 | $41.14 |
| Indicator | NHI | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 35.48 | 54.73 |
| Support Level | $69.69 | $12.54 |
| Resistance Level | $74.17 | $41.14 |
| Average True Range (ATR) | 1.22 | 1.80 |
| MACD | -0.12 | -0.91 |
| Stochastic Oscillator | 7.62 | 6.80 |
National Health Investors Inc is a self-managed REIT that owns, leases, operates, and finances the development of senior housing communities and medical facilities. It operates through two segments: Real Estate Investments and Senior Housing Operating Portfolio (SHOP). The Real Estate Investments segment, which generates the majority of revenue, includes real estate leases, mortgages, and other notes receivable related to independent living facilities, assisted living facilities, entrance fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment consists of ventures that own and operate independent living facilities. The company's revenues are derived from rental income, interest and other income, and resident fees and services.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.